← Leaderboards
Heath Devin Skinner
University Of Tx Md Anderson Can Ctr
$8,539,031
Attributed
$12,727,365
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,162,900 · 9
By mechanism
P50$10,319,517 · 3
R01$10,179,383 · 5
R21$664,000 · 1
Top collaborators
- Sunil Krishnan5 shared
- Curtis Pickering5 shared
- Robert L Ferris3 shared
- Thomas M Guerrero2 shared
- Jing Hong Wang1 shared
- Jianhua Xing1 shared
- Jose P. Zevallos1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Jaffer A. Ajani$4,835,162
- Yuan Ji$1,536,757
- Guojun Li$2,468,355
- Russell R Broaddus$6,374,452
- Cielito C Reyes-Gibby$3,873,330
Others in their field
Top investigators on “Radiation Therapy”
- Philip J Disaia · University Of California Irvine$132,438,187
- Walter John Curran · Thomas Jefferson University$132,004,598
- Richard L Schilsky · University Of Chicago$123,524,424
- Norman Wolmark · Nsabp Foundation, Inc.$104,937,424
- Monica M Bertagnolli · Strang Cancer Prevention Center$66,963,796
- Charles A Coltman · Southwest Oncology Group$64,545,998
Research focus
Radiation TherapyTumorHead And Neck CancerClinical TrialsResponseHead And Neck Squamous Cell CarcinomaMediatingIn VitroCellsToxic EffectSignal TransductionCohortRadiation ResponseRadiationBaseProteinsIn VivoPathway InteractionsBiological MarkersGenesDesignImmunePre-Clinical ModelRecurrence
Grant awards (30)
Head and Neck Cancer SPORE$2,154,331
P50 · FY2025 · CA · contact PI
Analysis of high dimensional genomic dataset to reveal mechanistic insights on divergent outcomes of head and neck cancer using system biology modeling coupled with experimental validation$1,899,042
R01 · FY2025 · DE
Targeting non-canonical p16 signaling to improve radiation response and outcome in head and neck cancer$583,698
R01 · FY2025 · DE · contact PI
Core A: Administrative Core$449,632
P50 · FY2025 · CA · contact PI
Project 2: Optimizing patient selection and deintensified therapy for human papillomavirus positive (HPV+) oropharyngeal cancer (OPC)$381,032
P50 · FY2025 · CA · contact PI
Head and Neck Cancer SPORE$2,030,091
P50 · FY2024 · CA
Targeting non-canonical p16 signaling to improve radiation response and outcome in head and neck cancer$572,025
R01 · FY2024 · DE · contact PI
Project 2: Optimizing patient selection and deintensified therapy for human papillomavirus positive (HPV+) oropharyngeal cancer (OPC)$327,972
P50 · FY2024 · CA · contact PI
Head and Neck Cancer SPORE$2,112,973
P50 · FY2023 · CA
Targeting non-canonical p16 signaling to improve radiation response and outcome in head and neck cancer$598,448
R01 · FY2023 · DE · contact PI
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma$563,756
R01 · FY2023 · DE
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticles$537,145
R01 · FY2023 · DE
Project 2: Optimizing patient selection and deintensified therapy for human papillomavirus positive (HPV+) oropharyngeal cancer (OPC)$350,923
P50 · FY2023 · CA · contact PI
Head and Neck Cancer SPORE$2,138,140
P50 · FY2022 · CA
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma$558,118
R01 · FY2022 · DE
Project 2: Optimizing patient selection and deintensified therapy for human papillomavirus positive (HPV+) oropharyngeal cancer (OPC)$374,423
P50 · FY2022 · CA · contact PI
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticles$270,816
R01 · FY2022 · DE
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma$563,756
R01 · FY2021 · DE
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticles$518,603
R01 · FY2021 · DE
Extension of Radiotherapy Research$334,519
R01 · FY2021 · CA · contact PI
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma$563,756
R01 · FY2020 · DE
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticles$518,603
R01 · FY2020 · DE
Extension of Radiotherapy Research$327,038
R01 · FY2020 · CA · contact PI
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma$567,457
R01 · FY2019 · DE
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticles$518,603
R01 · FY2019 · DE
Extension of Radiotherapy Research$324,482
R01 · FY2018 · CA · contact PI
Extension of Radiotherapy Research$17,518
R01 · FY2018 · CA · contact PI
Extension of Radiotherapy Research$342,000
R01 · FY2017 · CA · contact PI
Tumor mutation status will predict metabolic response to metformin in NSCLC$332,000
R21 · FY2015 · CA · contact PI
Tumor mutation status will predict metabolic response to metformin in NSCLC$332,000
R21 · FY2014 · CA · contact PI